Podcast

Modifying and optimizing a new era of glaucoma surgeries

Author(s):

Alex Delaney-Gesing ,Sheryl Stevenson

Oluwatosin U. Smith, MD, Glaucoma Associates of Texas, offers an update on optimization and surgical modifications of newer glaucoma surgeries in preop and postop settings.


Watch this interview: Optimizing and modifying new glaucoma surgeries

Listen to more EyePod episodes

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
Related Content
ZEISS VISULAS Combi availability expands to Canada
March 24th 2025

ZEISS VISULAS Combi availability expands to Canada

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Glaucoma Research Foundation announces 2025 recipients of Shaffer Research Grants
March 23rd 2025

Glaucoma Research Foundation announces 2025 recipients of Shaffer Research Grants

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries
March 20th 2025

Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries

OSRX expands medication sizes and adds direct-to-patient post-op kits
March 19th 2025

OSRX expands medication sizes and adds direct-to-patient post-op kits

© 2025 MJH Life Sciences

All rights reserved.